Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA. |  |
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Hamilton James C | Chief Discovery/Trans Medicine | Jan 06 '25 | Sale | 19.82 | 32,729 | 648,824 | 272,122 | Jan 07 09:28 PM | | O'Brien Patrick | COO and General Counsel | Jan 06 '25 | Sale | 19.82 | 29,184 | 578,539 | 535,201 | Jan 07 09:28 PM | | O'Brien Patrick | COO and General Counsel | Jan 07 '25 | Sale | 19.69 | 8,000 | 157,520 | 527,201 | Jan 07 09:28 PM | | Myszkowski Kenneth Allen | Chief Financial Officer | Jan 06 '25 | Sale | 19.83 | 27,167 | 538,595 | 473,433 | Jan 07 09:27 PM | | Myszkowski Kenneth Allen | Chief Financial Officer | Jan 07 '25 | Sale | 19.69 | 18,000 | 354,500 | 455,433 | Jan 07 09:27 PM | | Myszkowski Kenneth Allen | Officer | Jan 07 '25 | Proposed Sale | 19.69 | 10,000 | 196,877 | | Jan 07 05:01 PM | | Myszkowski Kenneth Allen | Officer | Jan 07 '25 | Proposed Sale | 19.69 | 8,000 | 157,529 | | Jan 07 04:49 PM | | O'Brien Patrick | Officer | Jan 07 '25 | Proposed Sale | 19.69 | 8,000 | 157,507 | | Jan 07 04:31 PM | | Anzalone Christopher Richard | Chief Executive Officer | Jan 02 '25 | Sale | 19.05 | 11,520 | 219,456 | 3,764,252 | Jan 06 06:07 PM | | Myszkowski Kenneth Allen | Officer | Jan 06 '25 | Proposed Sale | 19.82 | 5,817 | 115,318 | | Jan 06 05:48 PM | | Myszkowski Kenneth Allen | Officer | Jan 06 '25 | Proposed Sale | 19.82 | 9,255 | 183,476 | | Jan 06 05:40 PM | | Myszkowski Kenneth Allen | Officer | Jan 06 '25 | Proposed Sale | 19.80 | 6,287 | 124,452 | | Jan 06 05:33 PM | | Myszkowski Kenneth Allen | Officer | Jan 06 '25 | Proposed Sale | 19.82 | 5,817 | 115,320 | | Jan 06 05:26 PM | | Hamilton James C | Officer | Jan 06 '25 | Proposed Sale | 19.82 | 32,729 | 648,743 | | Jan 06 05:19 PM | | O'Brien Patrick | Officer | Jan 06 '25 | Proposed Sale | 19.82 | 29,184 | 578,456 | | Jan 06 05:05 PM | | Anzalone Christopher Richard | Officer | Jan 02 '25 | Proposed Sale | 19.04 | 11,520 | 219,392 | | Jan 02 04:16 PM | | OLUKOTUN ADEOYE Y | Director | Dec 27 '24 | Sale | 20.00 | 2,850 | 57,000 | 36,740 | Dec 30 05:12 PM | | OLUKOTUN ADEOYE Y | Director | Dec 27 '24 | Proposed Sale | 19.99 | 2,850 | 56,968 | | Dec 27 04:23 PM | | Anzalone Christopher Richard | Chief Executive Officer | Dec 23 '24 | Sale | 19.59 | 12,563 | 246,109 | 3,775,772 | Dec 23 04:39 PM | | Anzalone Christopher Richard | Officer | Dec 23 '24 | Proposed Sale | 19.59 | 12,563 | 246,085 | | Dec 23 04:16 PM | | Anzalone Christopher Richard | Chief Executive Officer | Dec 18 '24 | Sale | 21.24 | 26,712 | 567,486 | 3,688,335 | Dec 20 06:04 PM | | Waddill William D. | Director | Dec 17 '24 | Sale | 22.04 | 3,747 | 82,584 | 40,378 | Dec 18 06:19 PM | | Waddill William D. | Director | Dec 16 '24 | Sale | 21.90 | 3,748 | 82,081 | 44,125 | Dec 18 06:19 PM | | GIVEN DOUGLAS B | Director | Dec 16 '24 | Sale | 21.90 | 5,000 | 109,500 | 124,714 | Dec 18 06:18 PM | | GIVEN DOUGLAS B | Director | Dec 17 '24 | Sale | 22.04 | 547 | 12,056 | 124,167 | Dec 18 06:18 PM | | Vakiener Victoria | Director | Dec 16 '24 | Sale | 21.91 | 8,994 | 197,059 | 21,211 | Dec 18 06:15 PM | | Anzalone Christopher Richard | Officer | Dec 18 '24 | Proposed Sale | 21.24 | 26,712 | 567,415 | | Dec 18 04:41 PM | | GIVEN DOUGLAS B | Director | Dec 17 '24 | Proposed Sale | 21.98 | 547 | 12,026 | | Dec 17 05:06 PM | | Waddill William D. | Director | Dec 17 '24 | Proposed Sale | 22.03 | 3,747 | 82,552 | | Dec 17 04:53 PM | | Waddill William D. | Director | Dec 16 '24 | Proposed Sale | 21.89 | 3,748 | 82,056 | | Dec 16 04:44 PM | | Vakiener Victoria | Director | Dec 16 '24 | Proposed Sale | 21.91 | 8,994 | 197,066 | | Dec 16 04:30 PM | | GIVEN DOUGLAS B | Director | Dec 16 '24 | Proposed Sale | 21.89 | 5,000 | 109,470 | | Dec 16 04:15 PM | | Oliver Tracie | Chief Commercial Officer | Jul 02 '24 | Sale | 25.28 | 9,394 | 237,480 | 127,107 | Jul 03 05:27 PM | | Vakiener Victoria | Director | May 02 '24 | Sale | 23.31 | 1,799 | 41,935 | 30,205 | May 06 06:04 PM | | Hamilton James C | Chief Discovery/Trans Medicine | Apr 01 '24 | Sale | 28.03 | 6,000 | 168,180 | 204,851 | Apr 03 06:05 PM | | Lu Hongbo | Director | Mar 19 '24 | Buy | 28.00 | 1,000 | 28,000 | 32,680 | Mar 20 07:06 PM | | Lu Hongbo | Director | Mar 20 '24 | Buy | 27.50 | 1,000 | 27,500 | 33,680 | Mar 20 07:06 PM | | Lu Hongbo | Director | Mar 18 '24 | Buy | 27.49 | 1,000 | 27,490 | 31,680 | Mar 20 07:06 PM | | Myszkowski Kenneth Allen | Chief Financial Officer | Mar 06 '24 | Sale | 35.19 | 40,000 | 1,407,600 | 400,600 | Mar 08 05:54 PM | | Anzalone Christopher Richard | Chief Executive Officer | Jan 31 '24 | Option Exercise | 14.54 | 57,499 | 836,035 | 3,772,547 | Feb 02 05:25 PM | | Anzalone Christopher Richard | Chief Executive Officer | Jan 31 '24 | Sale | 32.35 | 57,499 | 1,860,019 | 3,715,048 | Feb 02 05:25 PM |
|
